Nathan Benaich discusses the rise of tech bio companies and how they differ from traditional biotech companies. He highlights the role of technology and software development in addressing problems in biology, as well as the modularization of the value chain in biotech. This shift has implications for reproducibility, capital efficiency, and the size of companies that can be created.
